Loading clinical trials...
Loading clinical trials...
Koanewa: A First in Human, Phase 1b, Open-label, Non-randomised, Single Dose Study to Assess the Safety and Tolerability of CTx1000 in Participants Diagnosed With Amyotrophic Lateral Sclerosis
Conditions
Interventions
AAV9 Gene therapy
Locations
1
Australia
Macquarie University Hospital
Sydney, New South Wales, Australia
Start Date
January 12, 2026
Primary Completion Date
December 1, 2027
Completion Date
December 1, 2030
Last Updated
February 10, 2026
NCT07235111
NCT07067229
NCT07175935
NCT06810219
NCT07295990
NCT05276349
Lead Sponsor
Celosia Therapeutics Pty Ltd
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions